Interstitial Cystitis (IC) also called as painful bladder syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder expands until it is full and then gives signal to the brain that it is time to urinate, communicating through pelvic nerves. With IC, these signals get mixed up and then patient feels the need to urinate more often and with smaller volumes of urine than most people. The IC disease most often affects women and can has a long-lasting impact on the quality of life. Although there is no cure, medications, and other therapies may offer some relief.
There are two types of IC such as non-ulcerative IC, which is found in 90% of the population suffering from IC. It is characterized by pinpoint hemorrhages called glomerulations. Another type of IC is Ulcerative IC, which comprises of about 5-10% of the patient population. It is mainly characterized by Hunner’s ulcers and the patches that bleed on bladder walls. Hunner’s ulcers, also called “Hunner’s lesions” or “Hunner’s patches”, are a sub type of IC and are not ulcers in the usual sense. They are distinctive areas of inflammation on the bladder wall that characterize the “classic” form of IC, and it affects only about 5 to 10 percent of patients suffering from IC.
Market Dynamics
The high prevalence of interstitial cystitis is driving the global interstitial cystitis drugs market. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. According to Patnaik et al., 2017, prevalence estimates suggest that 45 per 100,000 females and 8 per 100,000 men are diagnosed with IC in North America.
Key features of the study:
- This report provides in-depth analysis of the global interstitial cystitis drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global interstitial cystitis drugs market based on the following parameters – Company Highlights, Product Portfolio, Key Highlights, Financial Performance, and Market Strategies.
- Key companies covered as a part of this study include Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global interstitial cystitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interstitial cystitis drugs market
Detailed Segmentation:
- Global Interstitial Cystitis Drugs market, By Drugs:
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- Global Interstitial Cystitis Drugs market, By Route of Administration:
- Oral Therapy
- Intravesical Therapy
- Global Interstitial Cystitis Drugs market, By End User:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Interstitial Cystitis Drugs Market, By Region:
- North America
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Co.
- Johnson & Johnson
- Mylan NV
- Novartis AG
- Perrigo Co. Plc
- Pfizer Inc.
- Seikagaku Corp.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
